ライフサイエンスコーパス: insulin-like

1 These findings suggest that the reported insulin-like actions of GLP-1 receptor agonists that occ

2 synaptic function, could be preserved by the insulin-like effect of lipoic acid.

3 circulating monoamine oxidase activity, has insulin-like effects, and can initiate oxidative stress.

4 receptor, muscarinic 2), and RXFP1 (relaxin/insulin-like family peptide receptor 1).

5 One lying upstream of the relaxin/insulin-like family peptide receptor 2 ( RXP2) (chromoso

6 in adult males via interaction with relaxin/insulin-like family peptide receptor 2 (RXFP2).

7 rogenitor cells and upregulate expression of insulin-like genes in starved L1 larvae.

8 We further demonstrate that insulin like growth factor signaling may mediate the pro

9 However, the possible roles of the insulin like growth factor-1 receptor (IGF-1R) on neuron

10 Growth-related glycoproteins insulin-like growth factor (IGF) 1, IGF binding protein-

11 The insulin-like growth factor (IGF) axis may be implicated

12 however, data on mutations in IGF2, encoding insulin-like growth factor (IGF) II, are lacking.

13 stoma, is driven by Sonic hedgehog (Shh) and insulin-like growth factor (IGF) in the developing cereb

14 Signaling via the insulin-like growth factor (IGF) pathway is aberrantly a

15 The insulin-like growth factor (IGF) receptor (IGF-IR) is ne

16 Lowered insulin/insulin-like growth factor (IGF) signaling (IIS) can ext

17 the sirtuin family of proteins, the insulin/insulin-like growth factor (IGF) signaling (IIS) pathway

18 D) progression is significantly delayed when insulin-like growth factor (IGF) signaling is blocked in

19 The insulin/insulin-like growth factor (IGF) signaling pathway plays

20 Insulin-like growth factor (IGF) signaling plays an impo

21 d plasma protein-A (PAPP-A), which modulates insulin-like growth factor (IGF) signaling through prote

22 study is the identification of mutations in insulin-like growth factor (IGF) signalling genes in 8/1

23 The insulin-like growth factor (IGF) system is a well-studie

24 .0001), insulin (r(2) = 0.40, P < 0.005) and insulin-like growth factor (IGF)-1 (r(2) = 0.80, P < 0.0

25 The insulin/insulin-like growth factor (IGF)-1 signaling pathway (IS

26 AT3 phosphorylation by interleukin-6 (IL-6), insulin-like growth factor (IGF)-1, IGF-2, and leukemia

27 notype were accompanied by altered placental insulin-like growth factor (IGF)-2 expression and insuli

28 Aberrant regulation of the insulin-like growth factor (IGF)/insulin (IIS)-PI3K-AKT-

29 , including Wnt/beta-catenin, Prolactin, and insulin-like growth factor (IGF)1 signaling.

30 A focus on reversible mechanisms identified Insulin-like growth factor (IGF1) deficiency with inadeq

31 To determine the roles of insulin and insulin-like growth factor 1 (IGF-1) action in adipose t

32 ric dysfunction (EED) and disturbance of the insulin-like growth factor 1 (IGF-1) axis.

33 Human insulin-like growth factor 1 (IGF-1) is a 70 amino acid

34 Insulin-like Growth Factor 1 (IGF-1) is associated with

35 Insulin-like growth factor 1 (IGF-1) is known to have di

36 mones and neuropeptides, such as insulin and insulin-like growth factor 1 (IGF-1) likely modulate gly

37 spective case-control studies suggested that insulin-like growth factor 1 (IGF-1) or insulin-like gro

38 t or energy levels-most notably, the insulin/insulin-like growth factor 1 (IGF-1) signaling pathway,

39 nction through the regulation of the insulin/insulin-like growth factor 1 (IGF-1) signaling pathway.

40 liferation by modulating a decrease in serum insulin-like growth factor 1 (IGF-1) that allows GH rele

41 f the pro-osteoclastogenic factors RANKL and insulin-like growth factor 1 (IGF-1) to induce osteoclas

42 Finally, we studied the impact of insulin-like growth factor 1 (IGF-1) treatment on CDKL5

43 anismal level as shown by down-regulation of insulin-like growth factor 1 (IGF-1), a hallmark of prem

44 Serum levels of insulin-like growth factor 1 (IGF-1), a hormone with kno

45 pe 2 diabetes mellitus (T2DM) via binding of insulin-like growth factor 1 (IGF-1), an insulin-like ho

46 ng serum concentrations of glucose, insulin, insulin-like growth factor 1 (IGF-1), insulin-like growt

47 We previously established that an insulin-like growth factor 1 (IGF-1)-inducible mitochond

48 n-associated cytokines, macrophages released insulin-like growth factor 1 (IGF-1).

49 ress osteopontin (OPN) and receptors for the insulin-like growth factor 1 (IGF-1).

50 y, and low circulating levels of insulin and insulin-like growth factor 1 (IGF-1).

51 gate (MTA) showed an increased expression of insulin-like growth factor 1 (IGF-1).

52 +DE patient serum revealed altered levels of insulin-like growth factor 1 (IGF-I) and its binding pro

53 o-expression of two soluble proteins, namely insulin-like growth factor 1 (IGF1) and osteopontin (OPN

54 Insulin-like growth factor 1 (IGF1) and phosphoinositol

55 ingly, treatment of RTT-derived neurons with Insulin-like Growth Factor 1 (IGF1) could rescue some of

56 Insulin-like growth factor 1 (IGF1) has potent trophic e

57 novel MALDImmunoassay for quantification of insulin-like growth factor 1 (IGF1) in human plasma.

58 Insulin-like growth factor 1 (IGF1) is secreted in an au

59 receptor tyrosine kinases by neuregulin and insulin-like growth factor 1 (IGF1) leads to the phospho

60 ic species with high binding affinity to the insulin-like growth factor 1 (IGF1) receptor.

61 ffects of (56)Fe radiation on adipokines and insulin-like growth factor 1 (IGF1) signaling axis in mo

62 toxic inflammation, increases cytoprotective insulin-like growth factor 1 (IGF1) signaling, and preve

63 Human fibroblast growth factor 2 (FGF2) and insulin-like growth factor 1 (IGF1), are canonical proto

64 reased cellular sensitivity to estradiol and insulin-like growth factor 1 (IGF1), as measured in grow

65 or muscle growth, including the induction of insulin-like growth factor 1 (IGF1), as well as concomit

66 ted sites cluster on the binding surfaces of insulin-like growth factor 1 (IGF1), IGF1 receptor (IGF1

67 n, or co-overexpression of osteopontin (OPN)/insulin-like growth factor 1 (IGF1)/ciliary neurotrophic

68 cer pinpoint to a potential new function for insulin-like growth factor 1 (Igf1r) in the basal epithe

69 ands, and feet and are diagnosed by elevated insulin-like growth factor 1 levels and growth hormone l

70 Supplementation of insulin-like growth factor 1 partially reverted the DR-i

71 the insulin receptor (F-IRKO) or both IR and insulin-like growth factor 1 receptor (F-IR/IGFRKO).

72 atric skin display reduced activation of the insulin-like growth factor 1 receptor (IGF-1R) and alter

73 iates for the activation of PI3K by both the insulin-like growth factor 1 receptor (IGF-1R) and its c

74 Here, we found in the mouse that the insulin-like growth factor 1 receptor (IGF-1R) controls

75 rs revealed 6ha as preferential inhibitor of insulin-like growth factor 1 receptor (IGF-1R) in a pane

76 We have previously shown that the insulin-like growth factor 1 receptor (IGF-1R) transloca

77 tor 2 (IGF2) gene, encoding a ligand for the insulin-like growth factor 1 receptor (IGF-1R), in a sub

78 ession in this lineage and was stimulated by insulin-like growth factor 1 receptor (IGF1R) activation

79 in asthma, but little is known about how the insulin-like growth factor 1 receptor (IGF1R) affects as

80 s determined that LMP1 selectively activates insulin-like growth factor 1 receptor (IGF1R).

81 ang et al that describes a critical role for insulin-like growth factor 1 receptor in the progression

82 s as an autocrine activator of the beta-cell insulin-like growth factor 1 receptor signaling pathway.

83 2 (Cyclin D2), CCND1 (Cyclin D1), and IGF1R (insulin-like growth factor 1 receptor) genes involved in

84 t-mammalian target of rapamycin pathway, and insulin-like growth factor 1 receptor-targeted therapy h

85 apoptosis and liver injury by targeting the insulin-like growth factor 1 receptor.

86 gans strains with mutations in daf-2/insulin/insulin-like growth factor 1 receptor.

87 hanges in microRNA levels regulate SIRT1 and insulin-like growth factor 1 signalling.

88 story, medications, and laboratory findings (insulin-like growth factor 1, follicle-stimulating hormo

89 eased expression of pro-regenerative factors insulin-like growth factor 1, leukemia inhibitory factor

90 pinal cord, and normalization of circulating insulin-like growth factor 1.

91 model assessment of insulin resistance, and insulin-like growth factor 1.

92 ation but instead sustained signaling of the insulin-like growth factor 1/phosphatidylinositol 3-kina

93 The human insulin-like growth factor 2 (IGF2) and insulin genes ar

94 mouse hippocampus, induces the expression of insulin-like growth factor 2 (IGF2) for the stabilizatio

95 s Network detected the overexpression of the insulin-like growth factor 2 (IGF2) gene, encoding a lig

96 We addressed this question at the H19/insulin-like growth factor 2 (Igf2) imprinted locus, the

97 Insulin-like growth factor 2 (IGF2) is the major fetal g

98 IMPs, also known as insulin-like growth factor 2 (IGF2) messenger RNA (mRNA)

99 t that Hh markedly induces the expression of insulin-like growth factor 2 (Igf2) that activates the m

100 activating enzyme, deiodinase-III (Dio3) and insulin-like growth factor 2 (Igf2), genes that are know

101 Insulin-like growth factor 2 (IGF2), produced and secret

102 he expression of several myokines, including insulin-like growth factor 2 (IGF2), whereas RNAi and do

103 Loss of SRSF3 increases expression of insulin-like growth factor 2 and the A-isoform of the in

104 The gene encoding the Insulin-like Growth Factor 2 mRNA binding protein 2/IMP2

105 f the heterochronic let-7 miRNA pathway, the insulin-like growth factor 2 mRNA-binding protein 1 (IGF

106 Here, we determined that the RBP insulin-like growth factor 2 mRNA-binding protein 3 (IGF

107 ion in mutants exhibiting aberrant H19/Igf2 (insulin-like growth factor 2) imprinting.

108 iation [RalGDS/AF-6] domain family member 1, insulin-like growth factor 2, and adenomatous polyposis

109 or necrosis factor alpha and lower levels of insulin-like growth factor 2.

110 he growth-promoting and mitogenic effects of insulin-like growth factor 2.

111 ts known ability to promote the abundance of Insulin-like Growth Factor 2/IGF2, we find that IMP2 str

112 ing indicated substantial down-regulation of insulin-like growth factor binding protein (Igfbp) genes

113 Insulin-like growth factor binding protein (IGFBP)-1 inf

114 tor (PDGF) isoforms (PDGF-AA, -BB, and -AB), insulin-like growth factor binding protein (IGFBP)-2, an

115 Low circulating levels of insulin-like growth factor binding protein 1 (IGFBP-1) a

116 Insulin-like growth factor binding protein 1 (IGFBP-1) i

117 Insulin-like growth factor binding protein 2 (IGFBP2) is

118 that insulin-like growth factor 1 (IGF-1) or insulin-like growth factor binding protein 3 (IGFBP-3) w

119 sulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3),

120 K regulates Runx1-dependent transcription of insulin-like growth factor binding protein 3 (IGFBP3), a

121 -1, cartilage oligomeric matrix protein, and insulin-like growth factor binding protein 7 concentrati

122 Cartilage oligomeric matrix protein, insulin-like growth factor binding protein 7, and beta-g

123 In this setting, the insulin-like growth factor binding protein IGFBP7 inhibi

124 ide, interleukin-6, soluble CD40 ligand, and insulin-like growth factor binding protein-2) and 5 clin

125 ide, interleukin-6, soluble CD40 ligand, and insulin-like growth factor binding protein-2.

126 Reduction of prolactin, insulin-like growth factor binding protein-3, and matrix

127 atocyte growth factor, endocrine gland VEGF, insulin-like growth factor binding proteins, or endostat

128 Insulin and insulin-like growth factor I (IGF-I) signal through the

129 Disruption of insulin-like growth factor I (IGF-I) signaling is a key

130 AD in mice responds positively to decreased insulin-like growth factor I (IGF-I) signaling, a pathwa

131 mini nutritional assessment (P = 0.003), and insulin-like growth factor I (P = 0.002), and lowered C-

132 d tumor necrosis factor receptor 1 and lower insulin-like growth factor I and leptin.

133 Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new

134 onal immunoglobulin G1 antibody that targets insulin-like growth factor I receptor (IGF-IR).

135 ved growth factor receptor beta (Pdgfrb) and insulin-like growth factor I receptor (Igf1r) on T-ALL c

136 erum IL-6, tumor necrosis factor receptor 1, insulin-like growth factor I, and leptin.

137 human epidermal growth factor, insulin, and insulin-like growth factor I, particularly at the parasi

138 bolic variables, including glucose, insulin, insulin-like growth factor I, triglycerides, cholesterol

139 e gene that experiences LOI is the paracrine insulin-like growth factor IGF2, which occurs commonly i

140 ancer (insulinoma) cells that do not produce insulin-like growth factor II (IGF-II) grow slowly in pu

141 Since insulin-like growth factor II (IGF-II) receptors facilit

142 a systemic administration of the polypeptide insulin-like growth factor II (IGF-II) reverses all thes

143 st the effects of systemic administration of insulin-like growth factor II (IGF-II), a polypeptide th

144 antagomir-352 up-regulated the expression of insulin-like growth factor II receptor (IGF2R), which ma

145 Inhibition of the type 1 insulin-like growth factor receptor (IGF1R) reduces the

146 the MAPK pathway, PI3Kbeta, and PI3Kalpha or insulin-like growth factor receptor 1 (IGF1R) synergisti

147 receptor (EGFR) and insulin receptor (InsR)/insulin-like growth factor receptor 1 (IGF1R), as well a

148 ative inhibition, independent of insulin and insulin-like growth factor receptor activation.

149 4 seems to exert RIBEs by acting through the insulin-like growth factor receptor DAF-2.

150 to activate PI3K signaling downstream of the insulin-like growth factor receptor.

151 oward the insulin receptor and/or the type 1 insulin-like growth factor receptor.

152 Down-regulation of insulin/insulin-like growth factor signaling (IIS) can increase

153 The insulin/insulin-like growth factor signaling (IIS) pathway plays

154 e to their functional linkage to insulin and insulin-like growth factor signaling pathways.

155 o DNA damage repair, cell cycle progression, insulin-like growth factor signaling, innate immunity, a

156 Insulin/insulin-like growth factor signalling (IIS) is a critica

157 etabolic diseases and cancer are insulin and insulin-like growth factor signalling pathways.

158 a key role in regulating the growth hormone/insulin-like growth factor type 1 (GH/IGF1) axis, whose

159 inases, including the highly cancer relevant insulin-like growth factor type 1 receptor (IGF-1R).

160 Insulin-like growth factor type 2 (IGF2) receptor (IGF2R

161 eceptor isoforms A and B (IR-A and IR-B) and insulin-like growth factor type I receptor (IGF-1R).

162 Insulin receptor and insulin-like growth factor type I receptor abundance did

163 nockdown cells was associated with increased insulin-like growth factor- 1Rbeta (IGF-1Rbeta) levels.

164 growth while suppressing the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.

165 entified dysregulation of the Growth Hormone/Insulin-like Growth Factor-1 (GH/IGF-1) pathway as well

166 In addition to IRBP, the IPM also contains insulin-like growth factor-1 (IGF-1) and its associated

167 scular endothelial growth factor-A (VEGF-A), insulin-like growth factor-1 (IGF-1) and Klotho, in the

168 Insulin-like growth factor-1 (IGF-1) and signal transduc

169 recurrent GBM, driven by macrophage-derived insulin-like growth factor-1 (IGF-1) and tumor cell IGF-

170 e previously shown that systemic infusion of insulin-like growth factor-1 (IGF-1) exerts anti-inflamm

171 (PFNA), may alter levels of sex hormones and insulin-like growth factor-1 (IGF-1) in animals.

172 Exogenous Insulin-Like Growth Factor-1 (IGF-1) is neuroprotective

173 eurons, have triggered a renewed interest in insulin-like growth factor-1 (IGF-1) pathway activation

174 e MC4R, we assessed pulsatile GH release and insulin-like growth factor-1 (IGF-1) production and/or r

175 Activation of insulin-like growth factor-1 (IGF-1) receptor (IGF1R) si

176 In contrast, mice pretreated with insulin-like growth factor-1 (IGF-1) showed resolution o

177 atory pathway for E2F-2 production involving insulin-like growth factor-1 (IGF-1) signaling is simult

178 mediates adipogenesis and show a link to the insulin-like growth factor-1 (IGF-1) signaling pathway.

179 ells secrete a subthreshold concentration of insulin-like growth factor-1 (IGF-1) that primes the IGF

180 ce (95% CI) was computed for levels of serum insulin-like growth factor-1 (IGF-1), leptin, and adipon

181 elaborates the cardioprotective polypeptide, insulin-like growth factor-1 (IGF-1), which activates IG

182 ical stimulation that significantly promoted insulin-like growth factor-1 (IGF1) production and elici

183 ion and proliferation as well as insulin and insulin-like growth factor-1 (IGF1) receptor activation

184 eration, the expression of cellular insulin, insulin-like growth factor-1 (IGF1), and GHRH receptor,

185 actors released by astrocytes as insulin and insulin-like growth factor-1 (IGF1).

186 secretion of paracrine mediators, including insulin-like growth factor-1 (IGF1).

187 ained only a modest amount of variability in insulin-like growth factor-1 and insulin-like growth fac

188 tress syndrome were strongly associated with insulin-like growth factor-1 and insulin-like growth fac

189 Total insulin-like growth factor-1 and insulin-like growth fac

190 ignificantly influence circulating levels of insulin-like growth factor-1 and insulin-like growth fac

191 , SP and its metabolites in combination with insulin-like growth factor-1 are shown to promote the co

192 Perfluoroalkyl substances, sex hormones, and insulin-like growth factor-1 at 6-9 years of age: a cros

193 Evaluation III was strongly associated with insulin-like growth factor-1 levels; and age was strongl

194 TRPC6 complementation and by treatment with insulin-like growth factor-1 or hyperforin, a TRPC6-spec

195 The insulin-like growth factor-1 pathway was activated to a

196 Elevated IGF-1/insulin-like growth factor-1 receptor (IGF-1R) autocrine

197 In the present study, we report that insulin-like growth factor-1 receptor (Igf-1r) gene expr

198 Increased expression or signaling from the insulin-like growth factor-1 receptor (IGF-1R) has been

199 abolished these effects of insulin, whereas insulin-like growth factor-1 receptor (IGF-1R) silencing

200 The insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) are highly

201 -regulation of two of its targets: BCL-2 and insulin-like growth factor-1 receptor (IGF1R).

202 P-REX1 also promoted insulin-like growth factor-1 receptor activation, sugges

203 mmunohistochemical positivity for p4E-BP1 or insulin-like growth factor-1 receptor was statistically

204 Treatment with recombinant human insulin-like growth factor-1 restores responses of PV(+)

205 Impaired insulin/insulin-like growth factor-1 signalling (IGF-1) and insu

206 2 saturation and plasma glucose, insulin and insulin-like growth factor-1 were positively associated

207 ccumulation, which was confirmed in vitro as insulin-like growth factor-1, a known mediator of physio

208 ich was amplified by MCL-specific cytokines (insulin-like growth factor-1, B-cell activating factor,

209 as well as four long-lived mutants (insulin/insulin-like growth factor-1, dietary restriction, prote

210 changes including altered levels of insulin, insulin-like growth factor-1, leptin, adiponectin, stero

211 -1 and AKT following stimulation by insulin, insulin-like growth factor-1, or the neurotrophins (NGF

212 This potentiation is produced by insulin-like growth factor-1, whose binding proteins are

213 emoattractant protein-1, IL-6, IL-1beta, and insulin-like growth factor-1.

214 w this control is abrogated by inhibition of insulin-like growth factor-1R/INSR-driven phosphoinositi

215 Higher levels of apoptosis, reduced insulin-like growth factor-2 expression, and altered ant

216 IMP3 (insulin-like growth factor-2 mRNA binding protein 3) is

217 The insulin-like growth factor-2 mRNA-binding protein 1 (IGF

218 acellular domains of the mannose 6-phosphate/insulin-like growth factor-2 receptor (M6P/IGF2R), domai

219 xpression of the trophoblast survival factor insulin-like growth factor-2 was significantly lower.

220 d hepatocyte nuclear factor (HNF) 4alpha and insulin-like growth factor-binding protein (IGFBP) 1 mRN

221 Binding of STC2 prevents PAPP-A cleavage of insulin-like growth factor-binding protein (IGFBP)-4 and

222 esponse elements located in the promoters of insulin-like growth factor-binding protein 1 (IGFBP1) an

223 anges in microglial secretome and identified insulin-like growth factor-binding protein 1 (IGFBP1) as

224 everal genes, e.g., Sonic hedgehog (Shh) and Insulin-like growth factor-binding protein 2 (Igfbp2), t

225 Higher levels of insulin-like growth factor-binding protein 3 (IGFBP-3) m

226 The regulation of insulin-like growth factor-binding protein 3 (IGFBP3) ge

227 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 accurately

228 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in patients

229 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 in this pop

230 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 results in

231 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 significant

232 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 test was no

233 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 was 0.84 (0

234 owed by a marker of cell cycle arrest (urine insulin-like growth factor-binding protein 7) and, final

235 tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7.

236 g levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 early in cr

237 854746 is also significantly associated with insulin-like growth factor-binding protein-3 levels in t

238 ciated with insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 levels; Acu

239 Total insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 were measur

240 iability in insulin-like growth factor-1 and insulin-like growth factor-binding protein-3.

241 levels; and age was strongly associated with insulin-like growth factor-binding protein-3.

242 746 was significantly associated with plasma insulin-like growth factor-binding protein-3.

243 cancer model and decreased the expression of insulin-like growth factor-binding protein-5 (IGFBP5).

244 GFBP)-1 influences fetal growth by modifying insulin-like growth factor-I (IGF-I) bioavailability.

245 l and neuropsychological recovery, and serum insulin-like growth factor-I (IGF-I) may mediate this ef

246 In the total population, insulin-like growth factor-I (IGF-I)-enhanced cell cycle

247 ile hormone, 20-hydroxyecdysone, and insulin/insulin-like growth factor-like signaling in regulating

248 e growth regulator downstream of the insulin/insulin-like growth factor/Tor pathways.

249 clock function and elevated transcription of Insulin-like Growth Factor2 (Igf2).

250 ance of pancreatic cancer cells by secreting insulin-like growth factors (IGF) 1 and 2, which activat

251 oming a key regulator of metabolism, whereas insulin-like growth factors (IGF)-I/II are major growth

252 We show significant overexpression of insulin-like growth factors (IGFs) in association with I

253 This review discusses the role of the insulin-like growth factors (IGFs) in controlling placen

254 Insulin-like growth factors (IGFs) induce proliferation

255 Insulin and insulin-like growth factors I and II are closely related

256 The insulin-like growth factors IGF1 and IGF2 are closely re

257 s of the transforming growth factor-beta and insulin-like growth factors pathways, and extracellular

258 ng roles for cancer progression, such as the insulin-like growth factors.

259 itro, resulting in higher bioavailability of insulin-like growth factors.

260 Adaptor proteins in the insulin/insulin-like-growth factor-1 signaling pathways, such as

261 of insulin-like growth factor 1 (IGF-1), an insulin-like hormone that is involved in glucose homeost

262 ulin-like peptide 8 (Dilp8) as a relaxin and insulin-like molecule secreted from growing tissues that

263 nked ins-9 gene, which encodes a new agonist insulin-like peptide (ILP) expressed specifically in the

264 ally regulating the expression of a specific insulin-like peptide (ILP), INS-6.

265 thway revealed elevated levels of Drosophila insulin-like peptide 2 (Dilp2) in the IPCs and elevated

266 no acids promote the secretion of Drosophila insulin-like peptide 2 (Dilp2), circulating sugars promo

267 Insulin-like peptide 3 (INSL3) is a member of the relaxi

268 Insulin-like peptide 5 (INSL5) has recently been discove

269 We recently identified Drosophila insulin-like peptide 8 (Dilp8) as a relaxin and insulin-

270 we showed that the expression of Drosophila insulin-like peptide 8 (dilp8), which encodes a paracrin

271 lly regulates the expression of the secreted insulin-like peptide Dilp8.

272 n identified distinct peptides that regulate insulin-like peptide expression, feeding behavior, or bo

273 Insulin-like peptide mediated body size plasticity in Dr

274 aling leads to insufficient expression of an insulin-like peptide, dILP8, which is required for the d

275 ong-lived dietary restricted fruit flies and insulin-like-peptide mutants exhibit small nucleoli and

276 IIS models, namely Drosophila lacking three insulin-like peptides (dilp2-3,5(-/-)) and mice lacking

277 In Drosophila, insulin-like peptides (DILPs) are key regulators of meta

278 male-female differences in the production of insulin-like peptides (Ilps) from the IPCs do not appear

279 In this nematode, 40 insulin-like peptides (ILPs) have been identified as put

280 s, ovary ecdysteroidogenic hormone (OEH) and insulin-like peptides (ILPs), which activate multiple pr

281 In silico target prediction identified that insulin-like peptides 7 and 8 (ilp7 and ilp8) are putati

282 pendent signals that act systemically (e.g., Insulin-like peptides [ILPs] transduced by the Target of

283 the food odor benzaldehyde (BZ) and release insulin-like peptides and acetylcholine, respectively, w

284 We show that insulin-like peptides are produced and secreted normally

285 in, we show that in Drosophila expression of insulin-like peptides is regulated by neprilysin activit

286 response to photoreceptor-EGF, glia produce insulin-like peptides, which induce lamina neuronal diff

287 rons producing DH44, a CRH-like peptide, and insulin-like peptides.

288 ng those that secrete some of the Drosophila insulin-like peptides.

289 y to promote somatic differentiation through Insulin-like receptor (InR) activation.

290 ecipitation of Lin-28-bound mRNAs identified Insulin-like Receptor (InR), forced expression of which

291 n mutants that enhance dauer formation in an insulin-like receptor mutant (daf-2) background.

292 ration of prostate cancer cells by promoting insulin-like responses.

293 espan extension via the suppression of IGF-1/insulin-like signaling (IIS) offers a possibility to ret

294 n as dauer by inhibiting the conserved DAF-2 insulin-like signaling (ILS) pathway through incompletel

295 The insulin/insulin-like signaling and target of rapamycin (IIS/TOR)

296 hese pathways to extend life span, including insulin-like signaling and the response to dietary restr

297 ynthesis, and upstream components of insulin/insulin-like signaling are activated in their discs.

298 Furthermore, several insulin-like signaling effector genes were not significa

299 lent to normally pathogen-resistant DAF-2/16 insulin-like signaling pathway mutants.

300 lationship between components of the insulin/insulin-like/Tor and ecdysone pathways in the control of